Agoracom Blog Home

Posts Tagged ‘medical Marijuana’

Empower Clinics $EPW.ca gleans key patient insights from its artificial intelligence pilot program $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 8:57 PM on Tuesday, March 19th, 2019
  • Company is working with Canntop AI to identify insights for improvements to physician recommended treatment plans
  • “Insights derived from artificial intelligence are beginning to demonstrate how patients in our key markets are talking about or describing their experience and ideas related to cannabis/CBD-based treatments, and even suggesting recommendations about alternative therapies and their effectiveness in treating a wide array of qualifying conditions,” Empower CEO Steven McAuley said in a statement.

Empower owns and operates a vast network of physician-staffed clinics focused on helping patients through medical cannabis

Empower Clinics Inc (OTCMKTS:EPWCF) (CSE:EPW) told investors Tuesday that the artificial intelligence tools supplied by Canntop AI, a subsidiary of Datametrex AI Limited, was helping the medical cannabis company sift through mountains of data to create “actionable insights,” with the aim of improving patient care.

“Insights derived from artificial intelligence are beginning to demonstrate how patients in our key markets are talking about or describing their experience and ideas related to cannabis/CBD-based treatments, and even suggesting recommendations about alternative therapies and their effectiveness in treating a wide array of qualifying conditions,” Empower CEO Steven McAuley said in a statement.

The Vancouver cannabis company said it provided crucial SEO terms and phrases which Canntop integrated into the artificial intelligence platform so Empower could get more insights about its two largest markets in Portland and Phoenix. The whole idea rests on gaining “actionable insights” on how consumer social data is generating interest in CBD-based products, alternative pain management, and the use of cannabis-based therapies, said the company. 

“We believe the outcomes of our AI efforts, if successful, could position the company as an educational leader,” said McAuley. “We plan to collaborate with the industry with the ultimate goal of improving patient care.”

Artificial intelligence eliminates tedious data-sorting chores, and with machines using algorithms, it give them superhuman learning powers. Ultimately, AI gives companies like Empower, the tools to make faster, more accurate decisions after acquiring information about patients.

Powerful AI tools change the equation

“Canntop’s powerful AI tools are helping us analyze the substantial amounts of data in the Empower database and we expect will facilitate the integration of the additional data we expect to derive from the proposed acquisition of the Sun Valley Clinic group, that has a combined 165,000 patients,” said McAuley.

Empower has struck a non-binding deal to acquire the business of the Sun Valley Holdings, which operates a network of medical cannabis and pain management practices, with clinics in Arizona and Las Vegas as well as a tele-medicine platform serving California.

Empower utilizes a patient electronic management system that is HIPAA compliant and provides deep insight to patient care. The company’s tele-medicine platform also supports remote patients who use its portal when they are unable to come to a location, but still benefit from a doctor consultation.

“We are thrilled that Empower chose Canntop AI to be their partner for their artificial Intelligence needs. This is a great validation for our business model,” said Michael Frank, Chief Strategy Officer at Datametrex. “We believe this alliance between Canntop and Empower will create a strong platform for data analysis in the cannabis sector especially in the US, providing insurers and health care providers an ideal solution for patient care.”

Empower is a leading owner and operator of a network of physician-staffed clinics focused on helping patients improve their health through the use of medical cannabis.

Separately, Empower has also started selling its own line of CBD-based products called Sollievo via its network of company-owned clinics in the US. The offerings include CBD lotion, tinctures, spectrum oils, capsules, lozenges, patches, topical lotions, gel caps, e-drinks, hemp extract drops and pet elixir hemp extract drops.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Source: https://ca.proactiveinvestors.com/companies/news/216765/empower-clinics-gleans-key-patient-insights-from-its-artificial-intelligence-pilot-program-216765.html

#Marijuana Stocks: Three Key Catalysts for Further Growth $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 1:59 PM on Friday, October 26th, 2018

For most of 2018, marijuana stocks were the hottest opportunities around.

• Canopy Growth (CGC) ran from $20 to $57

• Tilray Inc. (TLRY) ran from $20 to $300

• OrganiGram Holdings (OGRMF) ran from $3 to $6.75

• Marijuana ETF, MJ ran from $26 to more than $44

All on anticipatory momentum as we neared Canadian approval this month. However, once the news was out, related stocks began to pull back on a “sell the news” reaction.

Once an expected catalyst is out, these are to be expected.

However, don’t count out marijuana stocks so fast, though. The catalysts ahead are monumental.

One – Americans Greatly Support its Legalization

A growing majority of Americans fully support its legalization, which has led to its decriminalization and the potential for significant cash inflows. In fact, 66% of Americans now support legalizing marijuana, another new high in Gallup’s trend. The latest figure marks the third consecutive year that support has increased.

Already, nine states and D.C. have legalized marijuana for recreational use.

As more states move to legalize its use, sales will skyrocket, in our opinion.

Two – Canada is Only the Start of the Boom

On October 17, 2018, marijuana became legal in Canada. But no one expected the demand to be as strong as it’s been. In fact, according to Fortune, the country can’t keep up with the pace of demand. Retail shops are nearly sold out.

It’s gotten so bad that stores have closed until the supply problem is fixed.

By 2021 analysts say Canada could have nearly four million recreational marijuana users, creating a monstrous $4.5 billion industry. The industry could balloon to $8.7 billion shortly thereafter, as marijuana retail sales just in Canada are likely to surpass beer, wine and spirit sales combined. That’s big money.

Three – Corporate America is on Board with Marijuana

As sales of beer fall in the United States, brewers have begun to bet that legalization of marijuana around the globe, especially the United States, will continue to build momentum and sales of cannabis products will take off.

Molson Coors for example listed legal cannabis among the biggest possible risks to its business in its annual shareholder report.

Even Bill Gates’ Microsoft jumped into the cannabis business on the software side, partnering with Kind Financial. The software will give governments and business owners a way to monitor the distribution of cannabis “from seed to sale” and ensure compliance.

Hewlett-Packard powers the Flowhub cannabis compliance solutions, too. Flowhub’s product not only provides business management and transactional processing tools for retail stores but also workflow focused on compliance, regulatory and reporting rules of marijuana dispensaries.

However, this is – we believe – is only the start. Pay close attention to this space.

Source: https://www.chasingmarkets.com/news/15bd33a6521b01/Marijuana_Stocks%3A_Three_Key_Catalysts_for_Further_Growth

Tetra Bio-Pharma’s $TBP.ca Evidence-Based Business Model Confirmed $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:13 AM on Friday, June 29th, 2018

Logo tetrabiopharma rgb web

  • Announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model.
  • Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence

Tetra Bio-Pharma provides extension to North Bud Farms

ORLEANS, Ontario, June 29, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model.  Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence. As a biopharmaceutical company, Tetra’s orientation is to bring cannabis and cannabinoid-based products to market that meet the regulatory quality, safety and efficacy requirements for prescription medications.

Health Canada recently issued a Notice of Intent to Amend the PDL to add phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids. In 2017, Tetra completed a major safety, pharmacokinetic and pharmacodynamic study in healthy human subjects that allowed Tetra to collect significant data to support its marketing applications. A similar clinical development program was launched with cannabis oils in preparation for the upcoming post-legalization market.  The combination of safety, pharmacokinetic and efficacy data allows Tetra to bring products to market under the proposed new regulatory framework.  Tetra Bio-Pharma is one of a few cannabinoid based companies that is committed to providing much needed clinical data for both its pharmaceutical and natural health products.

Over the coming months Tetra Bio-Pharma will deliver its findings in a series of presentations and scientific articles that will be published in 2018 to share the clinical data of both the inhalation and oral clinical development programs with the medical community,  beginning with the July 4, 2018 International Cannabinoid Research Society Meeting in the Netherlands where Dr. Maria-Fernanda Arboleda, MD, will present the results of the above clinical trial. http://www.icrs.co/SYMPOSIUM.2018/ICRS2018.PRELIMINARY.PROGRAMME.pdf ).  Tetra is a Gold Sponsor of this prestigious congress.

Update on North Bud Farms Inc.

Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the receipt of North Bud’s preliminary and final prospectus.  As one of the closing conditions to the sale these documents must now be submitted by July 31, 2018.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514

Media Contact:
energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209

Tetra Bio-Pharma $TBP.ca Adds a New Leader for its Commercial Operations $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:19 AM on Tuesday, June 19th, 2018

Logo tetrabiopharma rgb web

  • Announced that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations
  • He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health

Tetra Natural Health and Tetra Veterinary Health

ORLEANS, Ontario, June 19, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health.

Richard has more than 20 years’ experience in sales and marketing in the pharmaceutical industry from coast to coast. During his career, he has held various business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for various pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships through flexibility and efficiency. In the past 10 years, he was also a board member at the companies for which he worked.

“We’re very proud to add Richard Giguere to our senior management team. His vast experience in the sales and marketing of OTC, natural health products and original medications in the pharmaceutical industry across Canada will help drive the execution of our corporate strategy for our Tetra Natural Health and Tetra Veterinary Health divisions,” says Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.

Richard Giguere’s arrival is perfectly aligned with Tetra Bio-Pharma’s decision to restructure its corporation by commercial markets. While Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization of cannabinoid-based prescription drugs and treatments, Tetra Natural Health will develop and sell cannabinoid-based OTC (self-care) products to leverage the post-legalization market and Tetra Veterinary Health will focus on commercialization of cannabinoid-based products for the pet product market.

“I am honored to be able to play an active role in growing both the Tetra Natural Health and Tetra Veterinary Health divisions,” says Richard Giguere, EVP, Commercial Operations. “Tetra has a sound business model, and there are significant opportunities for us to grow our two commercial divisions. I am committed to making the best business and commercial decisions to accelerate the development of these huge potential markets for our cannabinoid-based products.”

As a result of this senior management change, Anne-Sophie Courtois left the corporation thereby terminating her role as Vice President, Marketing and Communications.

About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
More information at: www.tetrabiopharma.com

For further information, please contact Tetra Bio-Pharma Inc.
Guy Chamberland, Interim Chief Executive Officer
[email protected]

For investors information, please contact:
[email protected]
(438) 504-5784

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 M: 1 514 232 1556

FEATURE: Applied Biosciences – Poised to Succeed in CBD Market $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-Eric at 7:18 AM on Tuesday, May 29th, 2018

        

  • Consumer company with Multiple CBD Brands focused on Consumer, Pet, Female and Health and Wellness
  • Building brand with a scalable process and operation
  • Commenced sales of its hemp-derived CBD products on LeafLink’s industry-leading B2B e-commerce platform
  • Launched CBD product line under the Remedi CBD brand
  • Products will be sold on Remedi’s new website (www.remedishop.com) and in select locations in the U.S.
  • Launched CBD product line under TherPet brand (https://therpet.com/)
  • Currently shipping to the majority of US states and Internationally to 5 countries
  • Several strategic partnerships and investments currently in place
  • Partners include: High Times & GemmaCert

Key Market Drivers

     Increasing Momentum Towards Legalization

  • Especially related to medical -use Cannabis
  • Cannabis is legal in 29 states and the District of Columbia in some form ( or decriminalized )
  • International Opportunities: * Cannabis is now trading globally, with Canadian      grown Medical cannabis being exported to Germany, Croatia, New Zealand, Brazil and Chile. The Dutch are sending shipments of medical cannabis to Italy, Germany and Finland.   

     Shifting Public Opinion

  • Belief that the growth of the regulated cannabis industry has been fueled by changing public attitudes in the United States. A 2015 poll by Harris found 81% of Americans support the legalization of cannabis for medical use. Driven in part by this shift in public opinion.       

                        

 

 

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com
www.therpet.com

Follow us:

Facebook @remedicbd & @therpetcbd
Instagram @remedicbd & @therpet
Twitter @remedishop & @therpet

Namaste $N.ca $NXTTF signs exclusive distribution agreement with #Shatterizer and announces pod-based #vaporizer collaboration for the Canadian recreational cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:59 AM on Monday, May 28th, 2018

  • Signed an exclusive international distribution agreement with Shatterizer Inc.
  • Namaste will retain exclusive rights to sell Shatterizer’s innovative line of cannabis concentrate vaporizers in international markets
  • Company, through its wholly-owned subsidiary Infinite Labz Inc. (“Infinite Labz”), will produce cannabis oil and provide filling and distribution for Shatterizer’s upcoming pod-based concentrate vaporizer system

VANCOUVER, May 28, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N)(FRANKFURT: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that the Company has signed an exclusive international distribution agreement (the “Agreement”) with Shatterizer Inc. (“Shatterizer” or “Shatterizer.com”), whereby Namaste will retain exclusive rights to sell Shatterizer’s innovative line of cannabis concentrate vaporizers in international markets. Namaste is also pleased to announce that the Company will be working with Shatterizer to launch a pod-based vaporizer system for the Canadian recreational market. The Company, through its wholly-owned subsidiary Infinite Labz Inc. (“Infinite Labz”), will produce cannabis oil and provide filling and distribution for Shatterizer’s upcoming pod-based concentrate vaporizer system. Namaste is focused on leveraging its expertise in vaporizer technology within Canada, in an attempt to capitalize on what it anticipates being a significant market for concentrate pens and pre-filled cartridges in both the recreational and medical cannabis markets.

The Shatterizer vaporizer is designed for use with cannabis concentrates and extracts. The demand for high-potency cannabis concentrates has grown exponentially in the US and both Namaste and Shatterizer recognize the opportunity in the Canadian recreational and medical markets. The Shatterizer is engineered to produce a remarkably smooth draw, releasing the fullest flavor through the globe-shaped aluminum atomizer and mouthpiece so that users can enjoy the full-flavored taste of their concentrates. Since its trial launch on Namaste’s Canadian sites, the Shatterizer has received a 4.9/5 star consumer review score and has proven itself to be very popular with Namaste’s customers.

Terms of the Agreement:

  • Namaste will retain exclusive rights to sell Shatterizer products in international markets.
  • Namaste will offer Shatterizer products across its entire platform and stock inventory in its international warehouses.
  • Namaste will adhere to all minimum advertised prices (MAP) set forth by Shatterizer.
  • Shatterizer will provide Namaste’s customer service and sales team with training information and support.
  • Shatterizer will provide warranty support for Namaste’s customers in domestic and international markets.

Namaste anticipates an accelerated demand for cannabis oils and pre-filled cartridges and intends to use its hardware expertise to produce specifically formulated cannabis oil for pod-based vaporizer systems through Infinite Labz. Pre-filled cartridges and pods provide a very simple, discrete and effective means for consuming cannabis oils and extracts. Being the largest international online retailer of vaporizers, Namaste has the unique opportunity to capture early market share of this very significant component of the cannabis industry in the Canadian market. The Company will focus on production of high-quality cannabis oils with healthy margin to be sold through both recreational and medical sales channels. Namaste’s expertise with cannabis hardware and devices will provide a competitive edge in securing its position in this segment of the market.

Management Commentary

Matthew Zysman, President and CEO of Shatterizer comments; “We are thrilled to announce this international distribution deal with Namaste. We are pleased to see how successful we’ve been on their platform and are excited to see this relationship grow.

We at Shatterizer are firm believers that the future of the cannabis industry is in extracts and have built our business around this belief. Shatterizer has quickly become a popular brand amongst cannabis extract enthusiasts, and we are working hard daily to continually surpass our customer’s expectations. This is why we are also thrilled to announce that will be working with Namaste on our new pod-based cannabis vaporizer system in the Canadian market. We are excited to expand our relationship with Namaste, who has shown such great leadership in the cannabis industry and feel that they are the right partners to help us take the Shatterizer brand to the next level.”

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have entered into this distribution agreement with Shatterizer. We have been big supporters of the Shatterizer brand and are excited to collaborate on these initiatives. We believe that the company’s management team have a keen sense for market demand and we are aligned in terms of our outlook for the cannabis concentrate market. Our goal with Infinite Labz is to not only produce cannabis extracts but to also provide filling and distribution for pod-based vaporizer systems in which we anticipate seeing an increasing demand for the recreational cannabis market. We look forward to working with Shatterizer as they anticipate launching a new pod-based vaporizer platform in the near future. Namaste will continue to focus on securing similar strategic partnerships with innovative companies to service both recreational and medical cannabis markets.”

About Shatterizer

Shatterizer is focused on satisfying the cannabis concentrates and extracts specific community and growing with it. Customer dedication and continual innovation is the top priority. The company has developed an interchangeable portable vaporizer model, a borosilicate glass Shatterizer version and an aluminum version, increasing the overall product lifestylish-ness. The Shatterizer has come about as a result of personal experiences and the belief in a revolution in what we consume and how we consume it.

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press release.

Namaste $N.ca Signs Non-Binding LOI to Acquire Up to 25% Equity in Leading Same-Day Cannabis Delivery Service Pineapple Express Delivery Inc $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:30 AM on Wednesday, April 25th, 2018

Nlogo

  • Signed a non-binding letter of intent with Pineapple Express Delivery Inc.
  • Namaste will invest $1,000,000 to acquire 15% of the share capital of Pineapple Express and:
  • Obtain a right of first refusal to purchase an additional 10% of the share capital for an additional $1,200,000

VANCOUVER, British Columbia, April 25, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has signed a non-binding letter of intent (“LOI”) with Pineapple Express Delivery Inc. (“Pineapple Express”), whereby Namaste will invest $1,000,000 to acquire 15% of the share capital of Pineapple Express and obtain a right of first refusal to purchase an additional 10% of the share capital for an additional $1,200,000.

Pineapple Express currently operates a same-day delivery service for medical cannabis and expects to expand across Canada. Pineapple Express’ management team have a proven track record of launching cross-country same-day delivery services, having sold a previous same-day delivery venture to Just Eat Canada.

The proposed agreement will allow Namaste and Pineapple Express to expand on Pineapple Express’ existing same-day delivery service for medical cannabis platform to provide same-day delivery of medical cannabis across Canada. Namaste intends to assist with the development and marketing of Pineapple Express’ brand and in the optimization of its existing software platform. Namaste will also look to leverage its international exposure and offer Pineapple Express’ fully-integrated software application to international cannabis licensed producers.

The Company along with Pineapple Express will retain exclusive rights to use the Pineapple Express software platform in North America, and Namaste will hold the rights to use the software platform internationally. Pineapple Express has also signed an LOI with Canada’s leading seed-to-sale platform, Ample Organics Inc., to offer same-day delivery to its customers.

Terms of the LOI

  • Namaste will make an initial capital investment of $1,000,000 for 15% of the share capital of Pineapple Express. The initial capital investment will be comprised of $850,000 in cash and $150,000 in Namaste common stock, subject to exchange approval.
  • Namaste will receive a right of first refusal to acquire an additional 10% interest in Pineapple Express for $1,200,000 for 14 months following the closing date of the definitive agreement. This payment would be comprised of $780,000 in cash and $420,000 in Namaste common stock, subject to exchange approval.
  • Namaste will reserve for issuance up to 150,000 common share options (the “Options”) to be issued to Pineapple Express and/or its officers pursuant to consulting agreements entered into on execution of the definitive agreement. The Options will vest on a quarterly basis. Namaste will reserve up to 150,000 Options for issuance each year to Pineapple Express and/or its officers for so long as they have consulting agreements with Namaste.
  • Namaste and Pineapple Express will jointly hold the exclusive rights to Pineapple Express’ software and technology in North America. Namaste will solely hold the exclusive worldwide rights outside of North America to use Pineapple Express’ software and have a right to sublicense.

Management Commentary

Randy Rolph, President and CEO of Pineapple Express: “we are excited by the prospect of partnering with Namaste, as I see this as an excellent fit for both companies. Namaste has built an excellent reputation within the medicinal cannabis industry and has focused on expanding its services so that its customers benefit from a wider array of product offerings. As an extension of these efforts, we believe that our company can ensure their customers get a secure delivery of these products within a very quick turnaround from time of order. Through other businesses, we have successfully offered fast product delivery options for over 10 years across Canada, including same day as well as deliveries in less than one hour. We are familiar with the issues and most importantly the solutions to bring similar levels of service to the medicinal cannabis industry. Customer service has always been our main focus and what has driven the success of our business. We look forward to offering this same level of service to all customers.”

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to have signed this LOI to acquire shares of an amazing company offering a unique service with a proven record of success. As the cannabis market continues to grow, so too has the competitiveness among our industry peers looking to expand their market share. We believe that our ability to offer same-day delivery service for medical cannabis will provide a competitive edge to the Company in terms of offering an incredible buying experience for our patients. Namaste’s mandate from the outset has been focused on providing patients with unparalleled customer service. This transaction reaffirms our team’s ability to identify shortcomings within the cannabis industry, seek viable solutions, and then explore opportunities that aim to further enhance our patient’s experience. We believe this transaction will not only help Namaste attract new patients, but more importantly, it will help us retain patients who see value in the services we provide. We look forward to working with Pineapple Express’ management team and to grow its business and expand internationally. We are very grateful for this opportunity and look forward to cultivating a strong partnership together.”

About Pineapple Express Delivery Inc.

Pineapple Express’ management team has over 10 years of experience offering same-day 60-minute delivery services in multiple industries across Canada, and has successfully integrated with Ample Organics Inc., Canada’s leading seed-to-sale medical cannabis software platform. Pineapple Express offers a personalized experience for its customers and has established in depth security and delivery protocols to facilitate same-day delivery of medical cannabis across the country. Pineapple Express is dedicated to providing patients with a fully integrated, simple to use, same-day delivery platform which it believes brings great value to medical patients across the country. For more information visit: www.pineappleexpressdelivery.ca

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com

namastevapes.ca

everyonedoesit.ca

namastevaporizers.co.uk

everyonedoesit.co.uk

australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tetra Bio-Pharma $TBP.ca Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018 $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:05 AM on Thursday, April 12th, 2018

Logo tetrabiopharma rgb web

  • Provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization
  • authorization from the Office of Controlled Substances marks the initiation of the treatment phase of the Phase 2 clinical trial that will be used to support Product License Applications post legalization
  • Tetra is performing this clinical study to obtain safety and efficacy data to support modern claims for the use of encapsulated cannabis oils in the treatment of chronic pain

OTTAWA, ONTARIO–(April 12, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization.

Natural health products and OTC medications

The authorization from the Office of Controlled Substances marks the initiation of the treatment phase of the Phase 2 clinical trial that will be used to support Product License Applications post legalization. Tetra is performing this clinical study to obtain safety and efficacy data to support modern claims for the use of encapsulated cannabis oils in the treatment of chronic pain. Tetra’s program is designed to build a leading position in the development and commercialization of cannabis-based natural health products. Tetra’s products are being developed to be compliant with standards expected for pharmaceutical products which will be supported by scientific and clinical evidence.

PPP005 Phase 1 Clinical trial

Phase 1 clinical trial to assess safety, tolerability and pharmacokinetics of single and multiple dose of encapsulated cannabis oil (10 mg THC with 10 mg CBD) will be completed soon. “This study will provide cardiovascular safety data to ensure that the oil formulations can be safely used by consumers. The pharmacokinetic data will provide the data required to define the frequency of dosing needed to avoid inappropriate use that could lead to accumulation of cannabinoids in the body,” said Dr. Guy Chamberland, M.Sc., Ph.D., interim CEO and Chief Scientific Officer.

PPP005 Phase 2 Clinical trial

On March 22, 2018, Santé Cannabis, the Montreal-based clinic that is conducting the Phase 2 clinical trial for Tetra, received authorization from the Office of Controlled Substances to use the cannabis oil capsules of PPP005 (controlled substance).

This authorization allowed the Principal Investigator of the trial, Dr. Antonio Vigano, to proceed with the clinical trial of PPP005 in chronic pain patients. This exemption allows Santé Cannabis to prescribe the blinded study medication and for Aphria Inc to ship blinded products to patient’s home under the jurisdiction of the ACMPR. The screening and enrolment is proceeding faster than expected and will allow Tetra to meet its corporate objectives.

“We are performing this Phase 2 clinical trial to obtain safety and efficacy data to help drive the sales of encapsulated cannabis oil products for the treatment of chronic pain,” added Dr. Guy Chamberland. “We expect chronic pain patients to use cannabis oils, but many of these patients will also be taking opioids or other prescription medications. The capability of different doses and ratios of medical cannabis oil to change the amount and type of concomitant medications, such as opioids, used for pain, and the need for rescue pain medication to control chronic non-cancer and cancer pain is evaluated. The use of measures that quantify different pain drug regimens used by the patients will help us understand the potential of cannabis oils to be used for opioid sparing. The trial should be completed by fall 2018.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556

Tetra Bio-Pharma $TBP.ca Announces #FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:30 AM on Wednesday, March 14th, 2018

Logo tetrabiopharma rgb web

  • Announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to the active ingredients of its PPP001 drug for the treatment of complex regional pain syndrome 
  • FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA
  • Gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA

OTTAWA, ONTARIO–(March 14, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation.

The FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA. This designation gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA, and provides Tetra potential incentives such as access to federal grants and tax credits as well as a waiver of Prescription Drug User Fee Act filing fees.

Tetra successfully completed a placebo-controlled Phase 1a and 1b study of PPP001 in healthy volunteers and demonstrated that PPP001 can be safely consumed. “We are pleased to receive FDA Orphan Drug Designation for PPP001 and we look forward to discussing the clinical program with the US FDA that will be used to demonstrate the safety and efficacy in patients suffering from CRPS,” said Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer of Tetra.

According to the USA National Institute of Health, “complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb (arm, leg, hand, or foot) usually after an injury. CRPS is believed to be caused by damage to, or malfunction of, the peripheral and central nervous systems. CRPS is characterized by prolonged or excessive pain and changes in skin color, temperature, and/or swelling in the affected area.”

Appointment of a New Director – Tetra also announced the appointment of a new Director, Mr. Benoit Chotard, effective immediately. Mr. Chotard was previously a member of the Board of Directors from September 2016 to July 2017, he left for personal reasons, no longer applicable, and is pleased to come back. “We are glad to welcome back Mr. Chotard to the board and we look forward to working closely with him in building Tetra as a leading biopharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Mr. Chotard’s tremendous experience as an advisor of publicly listed companies will be a huge addition to our team. His local and international network will be a key factor in the Company’s growth.”

Benoit Chotard is a corporate finance & development executive who has over 20 years of international corporate finance, management and public market expertise. Previously, Mr. Chotard was employed as managing partner at Capital Force United, as President & CEO, and Director of Orletto Capital Inc., Vice-president Corporate Development for Pakit Inc., Senior Vice-president Finance Corporate Development and acting as Chief Financial Officer for CANTRONIC Systems (Canada) Inc., Vice-President Chief Financial Officer of Victhom Human Bionics, and spent eight years as Head of the Technology Investment Group of National Bank Financial Inc.

Mr. Chotard has been a Member of “Ordre des ingénieurs du Québec” since 1989 and obtained a bachelor’s degree in Chemical Engineering (1989) and a MBA (1993) from the Université de Sherbrooke.

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

For investors information, please contact:
[email protected]
(438) 504-5784

Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:04 AM on Monday, March 12th, 2018

15233 mcoa

  • Announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week,
  • One of the largest business-to-business trade shows in the world.

Escondido, California–(March 12, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week, one of the largest business-to-business trade shows in the world.

Convenient Hemp Mart has developed a collection of Benihemp branded, sample sized products for consumers including topicals, tinctures, and edibles packaged in 1-day, 2-day, and 30-day supplies. The target markets are convenience stores, smoke shops, gas stations and similar types of retail businesses where CBD commerce has a greater likelihood of generating sales from the impulse buyer at the register.

Convenient Hemp Mart is officially launching the Benihemp product line at ASD Market Week (www.asdonline.com) in Las Vegas, NV. ASD is a comprehensive business-to-business trade show for retail merchandise that annually hosts 45,000 buyers from over 90 countries, representing major department stores, convenience stores, gift shops, grocery stores, and other retail stores. Out of the 45,000 attending the show, 98% of the attendees have purchasing power, and the average buyer spends a total of $82,500 on product orders per show. Benihemp will be located in the lower south hall at booth SL2449.

MCOA has invested $100,000 into Benihemp in exchange for a 25% equity stake in Convenient Hemp Mart, LLC.

Donald Steinberg CEO of MCOA stated “Marijuana Company of America is excited for the opportunity to diversify product distribution into retail markets across the country. We believe in the Convenient Hemp Mart team and their ability to successfully launch Benihemp at ASD.”

“We are eagerly looking forward to the unveiling of the Benihemp brand at this ASD Marketplace event. With the ever-growing Convenience store marketplace hitting a new record of over 140 billion dollars in annual sales last year, we believe this is the perfect place to present the first industrial Hemp derived products developed specifically for this market. Our team has worked very diligently for the launch of the Benihemp brand and are all thrilled that it has finally come to life,” said Sam Girges of Benihemp.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our Benihemp Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]